Shots:

• The P-III PSOARING 3 LTE study evaluates tapinarof (1%- qd) vs vehicle-controlled cream in 763 patients with PsO for ~40wks. & a 4wks. safety follow-up period
• The results showed an improvement in efficacy beyond 12wks.- 58.2% of patients with PGA score ≥2 achieved a PGA score of 0 or 1 & 40.9% achieved complete disease clearance- the median duration of remitting effect (~4mos.) in patients with PGA score of 0- DoR (52wks.)- TEAEs were consistent with interim analysis & no new safety signals were identified
• Additionally- therapy is well tolerated & a safety profile was consistent with previous interim analysis. The FDA accepts an application with an anticipated PDUFA date in Q2’22

Ref: Businesswire | Image: Businesswire